Sequencing Remains Hot-Roche (RHHBY) Deal With Foundation Medicine (FMI) Worth $1.1B

Targeted Oncology Therapy-Molecular information from pathways and biomarkers e.g. PDL-1

  • RNA based immunotherapy test
  • Continuous  monitoring of tumor specific information and molecular alterations

All of our sequencing picks were up  1/12 on Roche equity deal to support oncology with personalized medicine development. Two other picks in the Rayno Dx and Tools Portfolio were also up :Pacific Biosciences (PACB) up over 5% and Illumina (ILMN) up 0.6%. FMI is up 103%.

Roche plc (RHHBY) is also on our focus list as a leader in diagnostics and oncology therapy with a broad pipeline.

We will update our sequencing plays : FMI, ILMN, PACB as well as notes from the seminar, “Harnessing the Power of Next Generation Sequencing”.

Pin It on Pinterest